Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + IBI310 in EBV+ Gastric Cancer
NCT04202601Phase 2Unknown
- Sponsor
- Peking University
- Start
- Dec 2019
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI310 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Peking University. Status: unknown.
02
Drugs
IBI310
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04202601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202601.